京東健康(06618.HK)跌幅擴至14% 遭大股東劉強東減持共套近4.4億元
京東健康(06618.HK)遭大股東劉強東減持合共套現近4.4億元,該股連跌兩天,今天一舉失守10天、20天及50天線(46.4-48.95元),午後跌幅擴至14%,報43元即市低位,成交708萬股。母企京東集團(09618.HK)也續跌4%曾低見238元。
聯交所權益披露顯示,京東集團(JD.US)創辦人兼主席劉強東分別於4月29日及5月3日以每股平均價50.67元及49元,分別於場內及場外先後減持京東健康384.28萬股及499.76萬股,合共套現近4.4億元。減持後,其於京東健康持股量由68.82%,降至68.66%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.